Jamjoom Pharmaceuticals Factory First Quarter 2025 Earnings: EPS: ر.س2.24 (vs ر.س1.47 in 1Q 2024)

Simply Wall St

May 08, 2025

Jamjoom Pharmaceuticals Factory (TADAWUL:4015) First Quarter 2025 Results

Key Financial Results

Revenue: ر.س457.5m (up 19% from 1Q 2024).
Net income: ر.س157.0m (up 53% from 1Q 2024).
Profit margin: 34% (up from 27% in 1Q 2024). The increase in margin was driven by higher revenue.
EPS: ر.س2.24 (up from ر.س1.47 in 1Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-growth — SASE:4015 Earnings and Revenue Growth May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jamjoom Pharmaceuticals Factory Earnings Insights

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Asia.

Performance of the market in Saudi Arabia.

The company's shares are down 2.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Jamjoom Pharmaceuticals Factory's balance sheet and an in-depth analysis of the company's financial position.

If you're looking to trade Jamjoom Pharmaceuticals Factory, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.